?Mirati Therapeutics, Inc.?(NASDAQ:?MRTX), a clinical-stage targeted oncology company, today announced a non-exclusive clinical collaboration agreement with Sanofi to evaluate the combination of?adagrasib, the Company's investigational KRAS^G12C?inhibitor, with Sanofi's investigational?SHP2?inhibitor?SAR442720, also known as RMC-4630. The Phase 1/2 dose escalation and expansion study will evaluate the combination in patients with previously-treated non-small cell lung cancer (NSCLC) and KRAS^G12C?mutations. "Mirati is aggressively advancing a broad?adagrasib?development program, which includes pursuing novel combination approaches including through this collaboration with Sanofi," said?Charles M. Baum, M.D., Ph.D.,?president, founder and head of research and development, Mirati Therapeutics, Inc. "There is strong scientific rationale for combining a?SHP2?inhibitor with?adagrasib, which may help optimize clinical outcomes for patients with KRAS^G12C-dependent tumors." SHP2?is upstream of KRAS and mediates cellular signaling through the RAS/MAP kinase pathway and is frequently overactive in various types of cancer. KRAS^G12C?inhibition and?SHP2?inhibition have complementary mechanisms of action and have demonstrated additive anti-tumor activity in pre-clinical models. Under the terms of the agreement,?Sanofi will be responsible for sponsoring and operating the Phase 1/2 study, and jointly with Mirati, will oversee and share costs of the study. About?Adagrasib?(MRTX849) Adagrasib?is an investigational, highly selective, and potent oral small-molecule inhibitor of KRAS^G12C?that is optimized to sustain target inhibition, an attribute that could be important to treat KRAS^G12C?mutated cancers, as the KRAS^G12C?protein regenerates every 24-48 hours.?Adagrasib?is a being evaluated as monotherapy and in combination with other anti-cancer therapies in patients with advanced KRAS^G12C-mutated solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer and pancreatic cancer. For more information visit?Mirati.com/science. About?SAR442720?(RMC-4630) SAR442720?(RMC-4630) is a potent and orally bioavailable small molecule that is designed to selectively inhibit the activity of?SHP2, an upstream cellular protein that plays a central role in modulating cell survival and growth by transmitting signals from receptor tyrosine kinases to RAS.?SAR442720?(RMC-4630) is the focus of an exclusive global development and commercialization agreement between Sanofi and Revolution Medicines. About Mirati Therapeutics, Inc. Mirati Therapeutics, Inc. is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Mirati is using its scientific expertise to develop novel solutions in two registration-enabling programs:?adagrasib?(MRTX849), an investigational small molecule, potent and selective KRAS^G12C?inhibitor, as monotherapy and in combination with other agents, and?sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. Mirati is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRAS^G12D?inhibitor, MRTX1719, an investigational PRMT5 inhibitor, and other oncology discovery programs. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer. For more information about Mirati Therapeutics Inc., visit us at?Mirati.com?or follow us on?Twitter?and?LinkedIn.? Forward Looking Statements This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati"). Any statement describing Mirati's goals, expectations, financial or other projections, intentions or beliefs, development plans and the commercial potential of Mirati's drug development pipeline, including without limitation?adagrasib?(MRTX849),?sitravatinib, MRTX1719 and MRTX1133, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to risks and uncertainties, particularly those challenges inherent in the process of discovering, developing and commercialization of new drug products that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Mirati's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Mirati's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Mirati. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Mirati's programs are described in additional detail in Mirati's quarterly reports on Form 10-Q and annual reports on Form 10-K, which are on file with the U.S. Securities and Exchange Commission (the "SEC") available at the SEC's Internet site (www.sec.gov).These forward-looking statements are made as of the date of this press release, and Mirati assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Mirati Contacts Investor Relations:?Temre Johnson?| 858-332-3562 |?ir@mirati.com Media Relations:?Priyanka Shah?| 908-447-6134 |?media@mirati.com SOURCE Mirati Therapeutics, Inc.

Related Links

https://www.mirati.com